WHO SMART Guidelines - HIV
0.3.0 - ci-build
WHO SMART Guidelines - HIV - Local Development build (v0.3.0) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions
| Official URL: http://smart.who.int/hiv/ValueSet/HIV.D.DE466 | Version: 0.3.0 | |||
| Active as of 2024-10-30 | Computable Name: HIVDDE466 | |||
Value set of type of treatment-limiting toxicity experienced by client. Treatment-limiting toxicity is defined as a serious adverse drug reaction that results in drug discontinuation or substitution. In addition, any reaction that leads to treatment interruption or requires changing the drug or regimen because of an adverse drug reaction is also considered a serious adverse drug reaction.
References
Generated Narrative: ValueSet HIV.D.DE466
http://smart.who.int/hiv/CodeSystem/HIVConcepts| Code | Display | Definition |
| HIV.D.DE467 | Gastrointestinal | Treatment-limiting toxicity due to GI issues (nausea, diarrhoea, abdominal pain, vomiting) |
| HIV.D.DE468 | Skin issues | Treatment-limiting toxicity due to skin issues (rash, hypersensitivity reaction) |
| HIV.D.DE469 | Peripheral neuropathy | Treatment-limiting toxicity due to peripheral neuropathy (burning/numbness/ tingling) |
| HIV.D.DE470 | Central nervous system symptoms | Treatment-limiting toxicity due to central nervous system symptoms (dizzy, anxiety, nightmare, depression, seizures) |
| HIV.D.DE471 | Weight gain | Treatment-limiting toxicity due to weight gain |
| HIV.D.DE472 | Hepatic dysfunction | Treatment-limiting toxicity due to hepatic dysfunction (jaundice) |
| HIV.D.DE473 | Haematological disorders | Treatment-limiting toxicity due to haematological (anaemia, neutropenia) disorders |
| HIV.D.DE474 | Fatigue | Treatment-limiting toxicity due to fatigue |
| HIV.D.DE475 | Headache | Treatment-limiting toxicity due to headache |
| HIV.D.DE476 | Bone dysfunction | Treatment-limiting toxicity due to bone dysfunction (fractures, osteopenia) |
| HIV.D.DE477 | Metabolic symptoms | Treatment-limiting toxicity due to metabolic symptoms (body fat changes, hyperglycaemia, dyslipidaemia) |
| HIV.D.DE478 | Kidney dysfunction | Treatment-limiting toxicity due to kidney dysfunction (nephrolithiasis, renal insufficiency) |
| HIV.D.DE479 | Unexpected adverse drug reaction | Client experienced an unexpected adverse drug reaction |
Generated Narrative: ValueSet
Expansion based on codesystem WHO SMART HIV Concepts CodeSystem v0.3.0 (CodeSystem)
This value set contains 13 concepts
| Code | System | Display | Definition |
| HIV.D.DE467 | http://smart.who.int/hiv/CodeSystem/HIVConcepts | Gastrointestinal | Treatment-limiting toxicity due to GI issues (nausea, diarrhoea, abdominal pain, vomiting) |
| HIV.D.DE468 | http://smart.who.int/hiv/CodeSystem/HIVConcepts | Skin issues | Treatment-limiting toxicity due to skin issues (rash, hypersensitivity reaction) |
| HIV.D.DE469 | http://smart.who.int/hiv/CodeSystem/HIVConcepts | Peripheral neuropathy | Treatment-limiting toxicity due to peripheral neuropathy (burning/numbness/ tingling) |
| HIV.D.DE470 | http://smart.who.int/hiv/CodeSystem/HIVConcepts | Central nervous system symptoms | Treatment-limiting toxicity due to central nervous system symptoms (dizzy, anxiety, nightmare, depression, seizures) |
| HIV.D.DE471 | http://smart.who.int/hiv/CodeSystem/HIVConcepts | Weight gain | Treatment-limiting toxicity due to weight gain |
| HIV.D.DE472 | http://smart.who.int/hiv/CodeSystem/HIVConcepts | Hepatic dysfunction | Treatment-limiting toxicity due to hepatic dysfunction (jaundice) |
| HIV.D.DE473 | http://smart.who.int/hiv/CodeSystem/HIVConcepts | Haematological disorders | Treatment-limiting toxicity due to haematological (anaemia, neutropenia) disorders |
| HIV.D.DE474 | http://smart.who.int/hiv/CodeSystem/HIVConcepts | Fatigue | Treatment-limiting toxicity due to fatigue |
| HIV.D.DE475 | http://smart.who.int/hiv/CodeSystem/HIVConcepts | Headache | Treatment-limiting toxicity due to headache |
| HIV.D.DE476 | http://smart.who.int/hiv/CodeSystem/HIVConcepts | Bone dysfunction | Treatment-limiting toxicity due to bone dysfunction (fractures, osteopenia) |
| HIV.D.DE477 | http://smart.who.int/hiv/CodeSystem/HIVConcepts | Metabolic symptoms | Treatment-limiting toxicity due to metabolic symptoms (body fat changes, hyperglycaemia, dyslipidaemia) |
| HIV.D.DE478 | http://smart.who.int/hiv/CodeSystem/HIVConcepts | Kidney dysfunction | Treatment-limiting toxicity due to kidney dysfunction (nephrolithiasis, renal insufficiency) |
| HIV.D.DE479 | http://smart.who.int/hiv/CodeSystem/HIVConcepts | Unexpected adverse drug reaction | Client experienced an unexpected adverse drug reaction |
Explanation of the columns that may appear on this page:
| Level | A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies |
| System | The source of the definition of the code (when the value set draws in codes defined elsewhere) |
| Code | The code (used as the code in the resource instance) |
| Display | The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application |
| Definition | An explanation of the meaning of the concept |
| Comments | Additional notes about how to use the code |